Get the Stockscreener App
31.88
2.18%
+0.68
Dyne Therapeutics Inc stock is currently priced at $31.88, with a 24-hour trading volume of 1.60M.
It has seen a +2.18% increased in the last 24 hours and a +25.96% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $31.35 pivot point. If it approaches the $31.91 resistance level, significant changes may occur.
Previous Close:
$31.20
Open:
$31.25
24h Volume:
1.60M
Market Cap:
$3.17B
Revenue:
-
Net Income/Loss:
$-235.94M
P/E Ratio:
-9.3765
EPS:
-3.4
Net Cash Flow:
$-188.89M
1W Performance:
+2.11%
1M Performance:
+25.96%
6M Performance:
+187.73%
1Y Performance:
+144.67%
1D Range:
$30.95
$32.04
52W Range:
$6.40
$35.98
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
781 786 8230
Address
830 Winter Street, Waltham
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics, Inc. (NASDAQ:DYN) Shares Sold by Swiss National Bank - Defense World
Defense World
Chardan Capital Comments on Dyne Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:DYN) - Defense World
Defense World
FY2024 EPS Estimates for Dyne Therapeutics, Inc. Boosted by Analyst (NASDAQ:DYN) - MarketBeat
MarketBeat
(DYN) On The My Stocks Page - Stock Traders Daily
Stock Traders Daily
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference - Investing News Network
Investing News Network
Dyne Therapeutics to Present at Jefferies Global Healthcare Conference - WDRB
WDRB
Dyne Therapeutics Inc Stock (DYN) Financials Data
Dyne Therapeutics Inc (DYN) Net Income 2024
DYN net income (TTM) was -$235.94 million for the quarter ending December 31, 2023, a -40.36% decrease year-over-year.
Dyne Therapeutics Inc (DYN) Cash Flow 2024
DYN recorded a free cash flow (TTM) of -$188.89 million for the quarter ending December 31, 2023, a -20.53% decrease year-over-year.
Dyne Therapeutics Inc (DYN) Earnings per Share 2024
DYN earnings per share (TTM) was -$3.94 for the quarter ending December 31, 2023, a -21.60% decline year-over-year.
Dyne Therapeutics Inc Stock (DYN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Beskrovnaya Oxana | Chief Scientific Officer |
May 20 '24 |
Sale |
32.96 |
30,426 |
1,002,751 |
149,647 |
| McNeill Jonathan | Chief Business Officer |
May 16 '24 |
Sale |
28.27 |
2,774 |
78,420 |
136,634 |
| HIGH SUSANNA GATTI | Chief Operating Officer |
May 16 '24 |
Sale |
28.27 |
2,738 |
77,402 |
154,062 |
| Beskrovnaya Oxana | Chief Scientific Officer |
May 16 '24 |
Sale |
28.27 |
2,705 |
76,469 |
149,647 |
| Scalzo Richard William | SVP, Head of Finance & Admin. |
May 16 '24 |
Sale |
28.27 |
2,588 |
73,162 |
116,695 |
| Farwell Wildon | Chief Medical Officer |
May 16 '24 |
Sale |
28.27 |
2,381 |
67,310 |
148,179 |
| Farwell Wildon | Chief Medical Officer |
Mar 12 '24 |
Sale |
25.58 |
1,030 |
26,347 |
150,560 |
| Brumm Joshua T | CEO & President |
Mar 11 '24 |
Option Exercise |
5.54 |
50,000 |
277,000 |
604,385 |
| McNeill Jonathan | Chief Business Officer |
Mar 11 '24 |
Option Exercise |
5.54 |
17,825 |
98,750 |
159,009 |
| Brumm Joshua T | CEO & President |
Mar 11 '24 |
Sale |
25.67 |
66,387 |
1,704,142 |
537,998 |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapies. The company was founded in 2017 and is based in Waltham, Massachusetts.
0.79%
3.50%
Cap:
|
Volume (24h):